Update on Treatment of Childhood Bronchiectasis unrelated to Cystic-Fibrosis

Paediatric Respiratory Reviews

Volumn 12, Issue 2, 2011, Pages 119-123

  Redding, Gregory J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiectasis treatment childhood

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; DEOXYRIBONUCLEASE; IBUPROFEN; IMMUNOGLOBULIN; INDOMETACIN; INFLUENZA VACCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MANNITOL; METHYLXANTHINE; PLACEBO; PNEUMOCOCCUS VACCINE; ROXITHROMYCIN; TIOTROPIUM BROMIDE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC PROPHYLAXIS; ASTHMA; BREATHING EXERCISE; BRONCHIECTASIS; BRONCHUS HYPERREACTIVITY; CHILD HEALTH CARE; CHILDHOOD DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY DYSKINESIA; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH PROGRAM; HEMOPTYSIS; HUMAN; IDIOPATHIC DISEASE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; LUNG TRANSPLANTATION; MUCOCILIARY CLEARANCE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPUTUM EXAMINATION; STREPTOCOCCUS PNEUMONIA; UNSPECIFIED SIDE EFFECT; WHEEZING;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; HUMANS; TREATMENT OUTCOME;

EID: 79953163675     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.10.012     Document Type: Review

References (50)

1. Banjar H.H. A review of 151 cases of pediatric noncystic fibrosis bronchiectasis in a tertiary care center. Ann Thorac Med Jan 2007, 2(1):3-8.
2. Chang A.B., Grimwood K., Mulholland E.K., Torzillo P.J. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002, 177:200-204.
3. Singleton R., Morris A., Redding G., et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000, 29(3):182-187.
4. Bahous J., Cartier A., Pineau L., et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984, 20(4):375-380.
5. Ip M., Lam W.K., So S.Y., Liong E., Chan C.Y., Tse K.M. Analysis of factors associated with bronchial hyperreactivity to methacholine in bronchiectasis. Lung 1991, 169(1):43-51.
6. Bastardo C.M., Sonnappa S., Stanojevic S., et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax Mar 2009, 64(3):246-251.
7. Notarangelo L.D., Plebani A., Mazzolari E., Soresina A., Bondioni M.P. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration 2007, 74(3):264-275.
8. Karadag B., Karakoc F., Ersu R., Kut A., Bakac S., Dagli E. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration May-Jun 2005, 72(3):233-238.
9. Lai S.H., Wong K.S., Liao S.L. Clinical analysis of bronchiectasis in Taiwanese children. Chang Gung Med J Feb 2004, 27(2):122-128.
10. Li A.M., Sonnappa S., Lex C., et al. Non-CF bronchiectasis: does knowing the aaetiology lead to changes in management?. Eur Respir J Jul 2005, 26(1):8-14.
11. Barker A.J., Couch L., Fiel S.B., et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
12. Kapur N., Masters I.B., Chang A.B. Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respir Med Nov 2009, 103(11):1681-1687.
13. Gaillard E.A., Carty H., Heaf D., Smyth R.L. Reversible bronchial dilatation in children. Comparison of serial high-resolution computed tomography scans of the lungs. Eur J Radiol 2003, 47:215-220.
14. Ellerman A., Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997, 10:2376-2379.
15. Haidopoulou K., Calder A., Jones A., Jaffe A., Sonnappa S. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol Jul 2009, 44(7):669-675.
16. Landau L.I., Phelan P.D., Williams H.E. Ventilatory mechanics in patients with bronchiectasis starting in childhood. Thorax 1974, 29:304-312.
17. Koh Y.Y., Lee M.H., Sun Y.H., Sung K.W., Chae J.H. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J May 1997, 10(5):994-999.
18. Yalcin E., Kiper N., Ozcelik U., et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31:49-55.
19. Cymbala A.A., Edmonds L.C., Bauer M.A., et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4:117-122.
20. Cole P.J., Roberts D.E., Davies S.F., Knight R.K. A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae. J Antimicrob Chemother 1983, 11:109-113.
21. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007; 2 (CD001392).
22. Redding G.J., Kishioka C., Martinez P., Rubin B.K. Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest Dec 2008, 134(6):1129-1134.
23. Bush A., Payne D., Pike S., Jenkins G., Henke M., Rubin B.K. Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis. Chest 2006, 129:118-123.
24. O'Donnell A.E., Barker A.F., Ilowite J.S., Fick R.B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest May 1998, 113(5):1329-1334.
25. Ramsey B.W., Dorkin H.L., Eisenberg J.D., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328:1740-1746.
26. Daviskas E., Anderson S.D., Gomes K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology Jan 2005, 10(1):46-56.
27. Daviskas E., Anderson S.D., Eberl S., Young I.H. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008, 31:765-772.
28. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Young I.H. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest Feb 2001, 119(2):414-421.
29. Daviskas E., Anderson S.D., Young I.H. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med Mar 2010, 104(3):371-377.
30. Brannan J.D., Porsbjerg C., Anderson S.D. Inhaled mannitol as a test for bronchial hyper-responsiveness. Expert Rev Respir Med Oct 2009, 3(5):457-468.
31. Kellett F., Redfern J., Niven R.M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med Jan 2005, 99(1):27-31.
32. Elkins MR, Jones A, Van der Schans C., Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2006; 2 (CD003147).
33. Murray M.P., Pentland J.L., Hill A.T. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J Nov 2009, 34(5):1086-1092.
34. Valery P.C., Purdie D.M., Chang A.B., Masters I.B., Green A. Assessment of the diagnosis and prevalence of asthma in Australian indigenous children. J Epidemiol 2003, 56(7):629-635.
35. Hassan J.A., Saadiah S., Roslan H., Zainudin B.M. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology Dec 1999, 4(4):423-426.
36. Li X.L., Cai S.X., Zhao H.J., et al. [Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis.]. Nan Fang Yi Ke Da Xue Xue Bao May 2010, 30(5):1072-1074.
37. Saito Y., Azuma A., Morimoto T., et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008, 47(7):585-591.
38. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2001; 4 (CD002155).
39. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2000; (4):CD002174.
40. Steele K, Greenstone M, Lasserson JA. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev 2001; (1): CD002734.
41. Auerbach H.S., Williams M., Kirkpatrick J.A., Colten H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985, 2:686-688.
42. Eigen H., Rosenstein B.J., FitzSimmons S., Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995, 126:515-523.
43. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; (1): CD000996.
44. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
45. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev; 4: CD007525.
46. Furumoto A., Ohkusa Y., Chen M., et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine Aug 5 2008, 26(33):4284-4289.
47. Eastham K.M., Fall A.J., Mitchell L., Spencer D.A. The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax Apr 2004, 59(4):324-327.
48. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; 2 (CD006316).
49. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; 18: CD006218.
50. Barlow C.W., Robbins R.C., Moon M.R., Akindipe O., Theodore J., Reitz B.A. Heart-lung versus double-lung transplantation for suppurative lung disease. J Thorac Cardiovasc Surg Mar 2000, 119(3):466-476.